{"protocolSection":{"identificationModule":{"nctId":"NCT07431086","orgStudyIdInfo":{"id":"HS-20094-OB-2569"},"organization":{"fullName":"Regeneron Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","officialTitle":"A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2026-03-18","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-11-14","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-19","type":"ESTIMATED"},"studyFirstSubmitDate":"2026-02-18","studyFirstSubmitQcDate":"2026-02-18","studyFirstPostDateStruct":{"date":"2026-02-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-18","lastUpdatePostDateStruct":{"date":"2026-02-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Regeneron Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity.\n\nThe study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes.\n\nThe study is looking at:\n\n* What side effects the study drug might cause\n* How much the study drug is in the blood at different times\n* How well the study drug works\n* If your body makes antibodies to the study drug, as this may cause the study drug to not work as well"},"conditionsModule":{"conditions":["Overweight or Obesity"],"keywords":["Body weight","Waist circumference","Glucagon-Like Peptide-1 (GLP-1) receptor agonist","Control appetite","Glucose-dependent Insulinotropic Polypeptide (GIP)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":120,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"General Cohort","type":"EXPERIMENTAL","interventionNames":["Drug: Olatorepatide","Drug: Placebo"]},{"label":"Subgroup Cohort","type":"EXPERIMENTAL","interventionNames":["Drug: Olatorepatide","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Olatorepatide","description":"Administered per the protocol","armGroupLabels":["General Cohort","Subgroup Cohort"],"otherNames":["HS-20094"]},{"type":"DRUG","name":"Placebo","description":"Administered per the protocol","armGroupLabels":["General Cohort","Subgroup Cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Occurrence of Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Severity of TEAEs","timeFrame":"Up to approximately 30 weeks"},{"measure":"Maximum plasma concentration (Cmax)","timeFrame":"At week 15 and week 24"},{"measure":"Area Under the Concentration time curve from time 0 to 168 hours (AUC0-168h)","timeFrame":"At week 15 and week 24"}],"secondaryOutcomes":[{"measure":"Percent change in body weight","timeFrame":"From baseline to week 25"},{"measure":"Change in mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP)","timeFrame":"From baseline to week 24"},{"measure":"Change in in-clinic SBP","timeFrame":"From baseline to week 24"},{"measure":"Lowest concentration in a dosing interval (Ctrough)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Time to Cmax (Tmax)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Apparent Volume of distribution (Vd/F)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Apparent clearance (CL/F)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Apparent terminal half-life (t½)","timeFrame":"Up to approximately 30 weeks"},{"measure":"Olatorepatide concentrations","timeFrame":"Up to approximately 30 weeks"},{"measure":"Occurrence of Anti-Drug Antibody (ADA) to olatorepatide","timeFrame":"Up to approximately 30 weeks"},{"measure":"Magnitude of ADA to olatorepatide","timeFrame":"Up to approximately 30 weeks"},{"measure":"Corrected QT interval (QTc)","timeFrame":"At 24 hours postdose"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Body mass index ≥27.0 kg/m\\^2 to \\<45.0 kg/m\\^2 at screening\n2. Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment\n\nKey Exclusion Criteria:\n\n1. History of Type 1 or Type 2 diabetes\n2. Change in body weight \\>5 kg within approximately 3 months before screening\n3. History of gastrointestinal (GI) surgery or procedures for weight management including bariatric surgery or planned bariatric surgery (includes removal or reversal, etc); presence of serious GI disorders (eg, active peptic ulcer, inflammatory bowel disease) and/or history of clinically significant gastric emptying abnormality or on chronic medication that alters GI motility\n4. Past medical history of moderate to severe depression or history of suicidal behavior, or past medical history of serious psychiatric disorder as described in the protocol\n5. History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years as described in the protocol\n\nNote: Other Protocol Defined Inclusion/ Exclusion Criteria Apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials Administrator","role":"CONTACT","phone":"844-734-6643","email":"clinicaltrials@regeneron.com"}],"overallOfficials":[{"name":"Clinical Trial Management","affiliation":"Regeneron Pharmaceuticals","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR","ANALYTIC_CODE"],"timeFrame":"When Regeneron has:\n\n* received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development\n* made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)\n* the legal authority to share the data, and\n* ensured the ability to protect participant privacy","accessCriteria":"Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf","url":"https://vivli.org/"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D050177","term":"Overweight"},{"id":"D009765","term":"Obesity"},{"id":"D001835","term":"Body Weight"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}